Pacific Biosciences Of California (PACB) Payables (2010 - 2026)

Pacific Biosciences Of California's Payables history runs 17 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• On a quarterly basis, Payables fell 3.05% year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $13.6 million, a 3.05% decrease from a year earlier, with the FY2025 full-year figure at $20.8 million, up 25.2% from the prior year.
• Payables retreated to $13.6 million in Q1 2026 per PACB's latest filing, from $20.8 million in the prior quarter.
• Across five years, Payables topped out at $21.0 million in Q1 2024 and bottomed at $12.1 million in Q3 2024.
• The 5-year median for Payables is $16.1 million (2023), against an average of $15.8 million.
• Across the five-year window, Payables jumped 407.26% in 2022 and slumped 33.18% in 2025, its largest moves.
• Year by year, Payables stood at $13.9 million in 2022, then gained by 8.59% to $15.1 million in 2023, then rose by 10.14% to $16.6 million in 2024, then grew by 25.2% to $20.8 million in 2025, then slumped by 34.48% to $13.6 million in 2026.
• Per Business Quant, the three latest PACB Payables figures stand at $13.6 million (Q1 2026), $20.8 million (Q4 2025), and $16.4 million (Q3 2025).